Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
GILD Gilead Sciences Inc
- Stocks
- Healthcare
- NASDAQ: GILD
Price (delayed)
$98.38
Market cap
$122.38B
P/E Ratio
20.62
Dividend/share
$3.1
EPS
$4.77
Enterprise value
$139.4B
Gilead Sciences, Inc. /ˈɡɪliəd/, is an American biopharmaceutical company headquartered in Foster City, California that researches, develops and commercializes drugs. The company focuses primarily on antiviral drugs used in the
Highlights
GILD's P/E is 93% below its last 4 quarters average of 296.4 and 84% below its 5-year quarterly average of 130.0
Gilead Sciences's equity has increased by 9% YoY
The quick ratio has grown by 39% YoY but it has contracted by 17% from the previous quarter
Key stats
What are the main financial stats of GILD
Market
Valuations
Earnings
Shares outstanding
1.24B
Market cap
$122.38B
Enterprise value
$139.4B
Price to earnings (P/E)
20.62
Price to book (P/B)
6.39
Price to sales (P/S)
4.27
EV/EBIT
17.85
EV/EBITDA
13.17
EV/Sales
4.85
Revenue
$28.74B
Gross profit
$22.5B
Operating income
$8.22B
Net income
$5.97B
EBIT
$7.81B
EBITDA
$10.58B
Free cash flow
$9.84B
Per share
Balance sheet
Liquidity
EPS
$4.77
EPS diluted
$4.75
Free cash flow per share
$7.9
Book value per share
$15.39
Revenue per share
$23.06
TBVPS
$23.09
Total assets
$56.43B
Total liabilities
$37.36B
Debt
$24.95B
Equity
$19.16B
Working capital
$4.56B
Debt to equity
1.3
Current ratio
1.37
Quick ratio
1
Net debt/EBITDA
1.61
Margins
Efficiency
Dividend
EBITDA margin
36.8%
Gross margin
78.3%
Net margin
20.8%
Operating margin
28.6%
Return on assets
10.7%
Return on equity
31.7%
Return on invested capital
23.4%
Return on capital employed
17.7%
Return on sales
27.2%
Dividend yield
3.15%
DPS
$3.1
Payout ratio
65%
GILD stock price
How has the Gilead Sciences stock price performed over time
Intraday
-3.01%
1 week
-0.53%
1 month
-7.62%
1 year
45.42%
YTD
6.51%
QTD
-12.2%
Financial performance
How have Gilead Sciences's revenue and profit performed over time
Revenue
$28.74B
Gross profit
$22.5B
Operating income
$8.22B
Net income
$5.97B
Gross margin
78.3%
Net margin
20.8%
GILD's gross profit is up by 8% YoY
GILD's revenue is up by 4.7% year-on-year
The gross margin has grown by 3.3% YoY
Price vs fundamentals
How does GILD's price correlate with its fundamentals
Growth
What is Gilead Sciences's growth rate over time
Valuation
What is Gilead Sciences stock price valuation
P/E
20.62
P/B
6.39
P/S
4.27
EV/EBIT
17.85
EV/EBITDA
13.17
EV/Sales
4.85
GILD's P/E is 93% below its last 4 quarters average of 296.4 and 84% below its 5-year quarterly average of 130.0
The stock's price to book (P/B) is 36% more than its 5-year quarterly average of 4.7 and 8% more than its last 4 quarters average of 5.9
Gilead Sciences's equity has increased by 9% YoY
GILD's price to sales (P/S) is 22% more than its 5-year quarterly average of 3.5 and 9% more than its last 4 quarters average of 3.9
GILD's revenue is up by 4.7% year-on-year
Efficiency
How efficient is Gilead Sciences business performance
Dividends
What is GILD's dividend history
DPS
$3.1
Dividend yield
3.15%
Payout ratio
65%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did Gilead Sciences financials performed over time
GILD's total assets is 51% higher than its total liabilities
The quick ratio has grown by 39% YoY but it has contracted by 17% from the previous quarter
Gilead Sciences's current ratio has increased by 27% YoY but it has decreased by 14% QoQ
Gilead Sciences's debt is 30% higher than its equity
The company's debt to equity fell by 10% YoY and by 6% QoQ
Gilead Sciences's equity has increased by 9% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.